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ABSTRACT
Young children and allogeneic hematopoietic cell transplantation (HCT) recipients respond poorly to polysac-
charide antigens, rendering them susceptible to severe infections because of encapsulated bacteria. This study
evaluated the responses of 127 HCT patients, median age 23.0 years, vaccinated with PNCRM7 andHaemophi-
lus influenzae (HIB) conjugate, 2 conjugate vaccines highly immunogenic in healthy children. Median time to
vaccination was 1.1 years after HCT. Sixty-two percent of patients responded to PNCRM7 (45 of 51 children,
34 of 76 adults, P\ .001). Overall response to HIB was 86%, including 77% of PNCRM7 nonresponders. Al-
though PNCRM7 response was adversely affected by older age (P\ .001), individuals $50 years old responded
significantly better if vaccinated following acquisition of specific minimal milestones of immune competence,
CD4 .200/mL, IgG .500 mg/dL, PHA within 60% lower limit of normal (11 of 19 versus 0 of 8, P\ .006). A
similar trend was observed in patients with limited chronic graft-versus-host disease (cGVHD). In all patients,
higher levels of circulating CD41CD45RA cells correlated with improved PNCRM7 response. These data dem-
onstrate that PNCRM7 is immunogenic in allogeneicHCTpatients, including older adults, but suggest that vac-
cination at fixed intervals after HCT, irrespective of immune competence, may limit its effectiveness.
Prospective, multicenter trials assessing the best strategy to administer this vaccine and its impact on pneumo-
coccal infections following transplantation are warranted.
 2008 American Society for Blood and Marrow Transplantation
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Invasive pneumococcal infections (IPIs) remain
a significant, potentially vaccine preventable cause of
morbidity and mortality late after successful allogeneic
transplantation [1-4]. Although IPIs are highest in pa-
tients with chronic graft-versus-host disease (cGVHD)
[1-5], the incidence in patients without GVHD is over
20 times that reported in the general population [1-5].
Using data prospectively collected by the Toronto In-
vasive Bacterial Diseases Network from 1995 through
2005, Kumar et al. [6] compared the incidence of IPIs
in adults 18 to 65 years of agewho did or did not receive
1022a hematopoietic cell transplant. The calculated inci-
dence of IPIs was 590 per 100,000 allogeneic transplant
recipients per year compared with 11.5/100, 000 per-
sons per year in nontransplanted individuals 18 to 65
years of age (P\ .0001). All pneumococcal strains iso-
lated from transplant patients were serotypes included
in the pure pneumococcal polysaccharide vaccine,
PPV23. Despite recommendations to use this vaccine
afterHCT [7,8], it is poorly immunogenic in transplant
recipients [9-11], contributing to a false sense of secu-
rity in PPV23 recipients of the vaccine and inconsistent
prescribing by health care professionals [5,6].
PNCRM7 and HIB in alloHCT 1023Table 1. Patient Characteristics
All Matched Related Unrelated Mismatched Related
N 5 127 n 5 67 n 5 53 n 5 7
Sex, % female 58 (45.7) 29 (43.3) 26 (48.2) 3 (42.9)
Age at transplant, median, y (range) 23 (0.1-64) 32 (0.1-64) 28 (0.2-62) 6 (0.8-9)
Diagnosis (%)
Acute Leukemia 64 (50.4) 38 (56.7) 20 (38.5) 2 (28.6)
Chronic Leukemia 6 (4.72) 4 (6.0) 2 (3.9) 0
Aplastic 26 (20.5) 8 (11.9) 11 (21.2) 3 (42.9)
Anemia/MDS
NHL/HD 13 (10.2) 6 (9.0) 7 (13.5) 0
Others* 18 (14.2) 11 (16.4) 3 (5.8) 2 (28.6)
Stem-Cell product (%)
Unmodified Transplant 56 (44.1) 35 (52.2) 20 (38.5) 1 (14.3)
T cell depleted transplant 71 (55.9) 32 (47.8) 32 (61.5) 6 (85.7)
TBI (%) 59 (46.5) 33 (49.3) 24 (46.2) 2 (28.6)
Acute GVHD (%) 10 (7.9) 5 (7.5) 5 (9.6) 0
Chronic GVHD (%) 25 (19.7) 14 (20.9) 11 (20.7) 0
Donor Leukocyte Infusion (%) 12 (9.4) 11 (16.4) 1 (1.9) 0
CD41 CD45RA1 Median, (range) 119 (0-1199) 110 (0.3-1029) 115 (0-1077) 360 (128-1199)In 2000, the FDA licensed the 7-valent protein-
conjugated pneumococcal vaccine (Prevnar
[PNCRM7]) containing 7 serotypes (4, 6B, 9V, 14,
18C, 19F, 23F) that cause 70% to 80% of invasive
pneumococcal infections in North America [12,13].
Five of the serotypes (6B, 9V, 14, 19F, 23F) are respon-
sible for the majority of antibiotic resistant pneumo-
coccal infections worldwide [12-14]. Conjugation of
pneumococcal saccharides to a carrier protein
(CRM197, a nontoxic variant of diphtheria toxin) re-
sults in T cell-dependent B cell generation of memory
B cells that respond to the attached sugars [12,13]. In
contrast, PPV23, elicits a T cell-independent B cell
response, and fails to induce antigenic memory, pre-
cluding the development of an anamnestic response
following antigenic reexposure [14]. PNCRM7 vacci-
nation has dramatically decreased the incidence of
pneumococcal disease in healthy infants and children
[15], populations who possess circulating B cells that
are phenotypically (CD201CD51CD381CD1c1)
and functionally similar to those of HCT recipients
[16].
To determine the response of allogeneic HCT
recipients to PNCRM7 compared with HIB, the im-
munization records and pre- and postvaccine titers of
all patients transplanted at Memorial Sloan Kettering
Cancer Center (MSKCC) between 2002 and 2005,
were analyzed for immunization against pneumococ-
cus. The effect of stem cell and donor type, use and
method of T cell depletion, presence of GVHD, and
receipt of donor leukocyte infusion (DLI) on vaccine
responses were assessed. The effect of PPV23 admin-
istration following the conjugate vaccine was also
analyzed.PATIENTS, MATERIALS, AND METHODS
Awaiver of authorization to conduct this study was
approved by the MSKCC institutional review board.
The medical records of all patients who remained dis-
ease free for 1 year after an allogeneic transplant
performed at this center from January 1, 12002
through December 31, 2005 were reviewed for immu-
nization against pneumococcus. Dates of vaccination
and pre- and post vaccine titers were obtained from
a prospectively maintained database and confirmed
by retrospective chart review. Of 189 patients who
survived disease free $1 year after HCT, 80% were
vaccinated against pneumococcus. Because of prelimi-
nary data demonstrating poor vaccine responses in pa-
tients immunized prior to the development of a CD4
cell count .200 cells/mL or IgG level .500 mg/dL,
75% of patients were vaccinated after achieving these
milestones. One hundred thirty-two patients received
a series of 3 PNCRM7 immunizations administered
4 to 8 weeks apart. Because of PNCRM7 shortages
during the study period, 21 patients (median age:
43.1 year) received PPV23 as their primary pneumo-
coccal vaccine. Pre- and postvaccine titers were
available in 127 of 132 PNCRM7 recipients (Table 1)
and 18 of 21 patients PPV23 recipients. Pre- and post-
vaccine titers were also analyzed in 36 of the 127 recip-
ients of PNCRM7 who received PPV23 as their
secondary pneumococcal vaccine. Ninety-four percent
of patients vaccinated with PNCRM7 received a con-
comitant series of Haemophilus influenza b conjugate
vaccines. Ninety percent of patients received at least 2
vaccines at MSKCC. All patients were evaluated at
MSKCC before and after completing vaccinations,
1024including assessment of acute GVHD (aGVHD) and
cGVHD using established criteria [17,18].
Serotype-specific pneumococcal capsular polysac-
charide IgG was measured by enzyme-linked immun-
sorbant assay (ELISA). The U.S. Food and Drug
Administration (FDA) standard reference serum 89-S
was used as the calibration standard. Titers against
pneumococcal serotypes 1, 3, 14, 19F, 23F, and 7F
were measured to distinguish responses specific
to PPV23 (1, 3, and 7F) from responses common to
both vaccines (14, 19F, and 23F). Response to
PNCRM7 or PPV23 was defined as seroconversion
or .3-fold rise in titer against serotypes 14, 19F, and
23F, 3 significant causes of antibiotic resistant pneu-
mococcal infections in HCT recipients [2,5]. Initial
antibody response was measured at a median of 3.0
months (range: 2-12 months) after completion of
PNCRM7 and HIB immunization. PPV23 response
was measured at a median of 3.2 months (range: 1.5-
12 months) following immunization. HIB response,
measured by ELISA, was defined as seroconversion
(.1 mg/mL) or .3-fold increase in antibody titer.
The lower limits of quantification for pneumococcal
and H flu antibody levels were 0.5 mg/mL and 0.15
mg/mL, respectively.
Immunofluorescence Studies
Two color immunofluorescence was performed
on the circulating lymphocytes all patients within 3
months of vaccine initiation. Directly fluoresceinated
(FITC) antibodies, including CD45 (common leuko-
cyte antigen, positive control), MsIgG, CD3 (pan T
cell), CD20 (pan B cell), CD14 (monocyte marker),
and phycoerythrin-conjugated (PE) antibodies
MsIgG, CD8 (cytotoxic or suppressor T cell marker),
CD4 (helper T cell), CD45RA (naı¨ve T cell subset),
and CD56 (natural killer cells) were purchased from
Becton Dickinson (Mountain View, CA). Immunoflu-
orescence was performed on whole blood as previously
described [19]. Immunofluorescence samples were
analyzed on a FACScan (Becton Dickinson). The lym-
phoid populations to be analyzed were gated on using
log 90 degree and forward-angle scatter characteris-
tics. The leukocyte-specific monoclonal antibody
CD45 was used to gate out any residual red cells.
Monocyte contamination was ruled out by lack of reac-
tivity (\1%) of the gated lymphoid cells with the
monocyte-specific marker CD14.
Patient and Transplant Characteristics
The demographics of the 127 patients vaccinated
with PNCRM7 are shown in Table 1. The median
age at HCT was 23.0 years (range: 0.1-64.0 years).
Thirty-three percent of the population was $40 years
old at HCT. The stem cell donor was an HLA-A, B,
DRb1 identical sibling, an HLA-mismatched familymember, or unrelated donor in 53%, 5.5%, and 42%
of cases, respectively. Fifty-six percent of patients re-
ceived a T cell-depleted bone marrow or peripheral
blood stem cell (PBSC) product. T cells were depleted
from bone marrow by soybean lectin agglutination,
followed by rosetting with sheep erythrocytes (n 5
16) [20], and from peripheral blood by CD34 positive
selection followed by rosetting with sheep erythro-
cytes (n 5 55) [21]. The majority (84%) of recipients
of an unmodified HCT received either short-course
methotrexate (MTX) combined with tacrolimus or cy-
closporine (Cy; n 5 33) or Cy and alemtuzumab (n 5
14) for GVHD prophylaxis. Of the 56 patients who re-
ceived an unmodified HCT, 26% developed cGVHD,
of whom 32%were on immunosuppression at the time
of revaccination.
Twelve patients received adoptive immunotherapy
in the form of unfractionated donor lymphocytes for
the treatment (n 5 2) or prevention (n 5 1) of an
EBV-LPD, to prevent recurrent malignancy (n 5 6),
or to treat mixed T cell chimerism (n 5 3). Twelve
patients received posttransplant rituximab for the
treatment or prevention of an EBV-LPD (n 5 9),
treatment of an autoimmune cytopenia (n5 2), or pre-
vention of recurrence of a CD201 malignancy [1].
Twelve patients received the CD20 monoclonal anti-
body, rituximab, for the treatment of an autoimmune
hemolytic anemia (n 5 1), treatment (n 5 2), or pre-
vention (n 5 7) of an EBV lymphoproliferative disor-
der, or prevention of recurrence of a CD201
malignancy (n 5 2). Rituximab was administered at
a median (range) of 252 (135-728) days prior to revac-
cination.
Biostatistics
Frequency distributions for characteristics of
patients by donor type and response to vaccination
was summarized in Tables 1-3. Fisher’s exact test
and the Wilcoxon rank sum test were used to examine
covariate differences between responders and nonre-
sponders. Subsequent to the univariate analyses, a lo-
gistic regression model was developed to determine
the set of factors that independently predicted vaccine
response. TheHosmer and Lemeshow goodness-of-fit
statistic was used to assess how close the model-
predicted values were to the corresponding observed
values [22]. The statistical packages SAS (9.1) and R
(2.3.1) were used to generate the test statistics and
build the regression model.
RESULTS
There were no serious adverse reactions in any
patient attributable to vaccination with PNCRM7.
PPV23, or HIB. Prior to revaccination, over 80%
of patients lacked detectable titers against any pneu-
mococcal serotype and Haemophilus influenzae. The
M. Pao et al.
PNCRM7 and HIB in alloHCT 1025Table 2. Characteristics of Prevnar responders and nonresponder
Responder Nonresponder
Characteristics N 5 79 N 5 48 Univariate Multivariate
Median age (range) 15 (0.1-59) 40.5 (0.7-64) \0.001 0.001
Sex, male, no. (%) 39 (49.4) 30 (62.5) 0.20
*Diagnosis, no. (%) 0.03 0.27
Acute Leukemia 37 (46.8) 27 (56.3)
Chronic Leukemia 4 (5.1) 2 (4.2)
Aplastic Anemia/MDS 19 (24.1) 7 (14.6)
NHL/HD 4 (5.1) 9 (18.8)
Others 15 (19.0) 3 (6.3)
Graft type, no. (%) 0.46
Unmodified Transplant 37 (46.8) 19 (39.6)
T Cell depleted Transplant 42 (53.2) 29 (60.4)
Donor, no. (%) 0.09
HLA-matched related 39 (49.4) 28 (58.3)
HLA-mismatched related 7 (8.8) 0
Unrelated 33 (41.8) 20 (41.7)
TBI regimen, no. (%) 36 (45.6) 23 (47.9) 0.85
DLI, no. (%) 2 (2.6) 10 (20.9) 0.001 0.06
Acute GVHD, no (%) 9 (11.4) 1 (2.1) 0.08
Chronic GVHD, no. (%) 18 (22.8) 7 (14.6) 0.35
Natural Log
CD41/CD45RA1 Median (range) 5.0 (-4.6-7.1) 4.4 (-4.6-6.4) 0.004 0.21median time to initiate vaccination with PNCRM7
andHIB was 1.1 years post-HCT. Forty percent of pa-
tients were immunized within 1 year and 81%within 2
years of transplant. There was no significant difference
in the time to PNCRM7 vaccination in recipients of
a T cell-depleted versus an unmodified (T cell replete)
transplant (median 1.0 year versus 1.14 years, P 5 .3).
The median time to vaccination in children and adults
was 1 year and 1.3 years, respectively (P\ .001). The
shorter interval between HCT and vaccination of chil-
dren was in part because of more rapid immune recon-
stitution in patients\18 years of age combined with
the tendency of pediatricians to vaccinate immediately
after the milestones were met. In the 25 patients with
cGVHD, the median time to vaccination was 1.8 years
compared to 1.1 years in patients without GVHD
(P\ .001).
Sixty-two percent (79 of 127) of patients re-
sponded to PNCRM7 (Table 2a, 2b). A dichotomy
existed between the response observed in children
(median age: 9 years (0.1-17.9) and adults (median
age: 41 years [range: 18-64]). Eighty-eight percent
of children responded to the heptavalent pneumococ-
cal conjugate vaccine compared to 44% of adults (P\
.001). In contrast, only 1 of 18 patients, median age
42.5 years, immunized with PPV23 responded to se-
rotypes 14, 19F, and 23F. Of the 16 adult recipients
of PPV23, only 1 of 16 responded compared to 34
of 76 adults given the conjugated vaccine (P 5
.003). PNCRM7 response in children and adults was
not affected by the use of T cell depletion or donor
type (Table 2b). Five of 12 patients who received
rituximab responded to PNCRM7, including 2 of 4Table 2b. PNCRM7 response in children (upper) and adults (lower)
Children\18 yrs
Median age: 9 years
Range: 0.1-17.9
Overall Response 45/51 (88%)
Transplant type P 5 0.67
Unmodified 23/27 (85%)
T-cell depleted 22/24 (92%)
Donor Type P 5 0.40
HLA-matched Related 22/24 (92%)
Unrelated 16/20 (80%)
HLA-MM related 7/7 (100%)
HLA-matched related P 5 0.53
Unmodified 14/16 (88%)
T-cell depleted 8/8 (100%)
Unrelated donor P 5 1.00
Unmodified 8/10 (80%)
T-cell depleted 8/10 (80%)
Adults .18yrs,
Median 41 yrs
Range: 18.0-64.0
Overall response 34/76 (44%)
Transplant type P 5 0.63
Unmodified 14/29 (48%)
T-cell depleted 20/47 (43%)
Donor Type P 5 0.35
Related 17/43 (40%)
Unrelated 17/33 (52%)
HLA-matched related P 5 0.20
Unmodified 10/19 (53%)
T-cell depleted 7/23 (30%)
Unrelated donor P 5 0.46
Unmodified 4/10 (44%)
T cell depleted 13/23 (57%)
1026children and 3 of 8 adults. For PNCRM7 vaccination,
results from multivariate logistic regression model in-
dicated that age at transplant significantly predicted
response (P 5 .0002). DLI and disease diagnosis
were associated with response, but did not signifi-
cantly predict response after adjusting for age at trans-
plant (Table 2a).
HIB response was evaluable in 115 of 127 recipi-
ents of PNCRM7 and 13 of 18 recipients of PPV23.
Overall, 86% of PNCRM7 recipients responded to
HIB, including 96% of children (48 of 50) and 79%
(51 of 65) of adults (P 5 .006). Response to the HIB
conjugate vaccine was observed in 77% and 100% of
patients who failed PNCRM7 or PPV23, respectively.
Because age was the only prognostic factor associated
with response to the HIB conjugate vaccine, a single
variable logistic regression model was used to predict
the probability of response based on age at transplant
(Table 3). A graph depicting the probability of re-
sponse to HIB and PNCRM7 based on the age at
transplant is shown in Figure 1.
Correlation of PNCRM7 response with in vitro
parameters of immune reconstitution including the
PHA response and circulating numbers of CD3,
CD4, CD41CD45RA naı¨ve T cells, CD8, and CD19
cells/mL was evaluated. In patients .50 years of age,
11 of 19 patients vaccinated after reaching minimal
milestones of immune reconstitution (CD4 .200/
mL, IgG .500 mg/dL, PHA within 60% lower limit
of normal) responded to PNCRM7, compared with
0 of 8 vaccinated prior to reaching these milestones
(P 5 .006). Among patients vaccinated after achieving
minimal milestones of immune reconstitution, there
was no correlation between response and the absolute
Table 3. Characteristics of Hib responders and nonresponder
Responder Nonresponder
Characteristic N 5 99 N 5 16 P Value
Median age (range) 18 (0.1-64) 34.5 (0.7-62) 0.07
Sex, male, no. (%) 54 (54.6) 10 (62.5) 0.60
Diagnosis, no. (%) 0.22
Acute Leukemia 51 (51.5) 6 (37.5)
Chronic Leukemia 4 (4.0) 2 (12.5)
Aplastic Anemia/MDS 21 (21.2) 4 (25)
NHL/HD 8 (8.1) 3 (18.8)
Graft type, no. (%) 0.78
Unmodified Transplant 43 (43.4) 8 (30.0)
T Cell depleted
Transplant
56 (56.6) 8 (50.0)
Donor, no. (%) 0.75
Matched related 49 (49.5) 9 (56.2)
Mismatched related 7 (7.1) 0
Unrelated 43 (43.4) 7 (43.7)
TBI regimen, no. (%) 45 (45.5) 8 (50.0) 0.79
DLI, no. (%) 7 (7.1) 1 (6.3) 1.0
Acute GVHD, no (%) 8 (8.1) 1 (6.3) 1.0
Chronic GVHD, no. (%) 20 (20.2) 3 (18.8) 1.0level of CD3T cells, CD81T cells, CD4, or CD191 B
cells (data not shown). In contrast, the level of circulat-
ing CD41CD45RA1 cells/mL, P \ .01, correlated
with response (Figure 2).
Twenty-seven patients who did not respond to an
initial series of PNCRM7 were subsequently vacci-
nated with PPV23 (n5 16) or received a second series
of PNCRM7 (n 5 11). Patients were vaccinated at
a median of 270 days following their last pneumococ-
cal vaccine. Four (25%) patients responded to PPV23
and 7 (44%) to a second series of PNCRM7 (P5 .06).
Ten patients who failed PPV23 as their initial pneu-
mococcal vaccine received a second PPV23 (n 5 4)
or were immunized with a series of PNCRM7 (n 5
6). Five of 6 patients responded to PNCRM7 com-
pared with 0 of 4 given a second PPV23. Response to
Figure 1. Predicted probability of response to PNCRM7 and HIB
from logistic regression model by age at transplant.
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Figure 2. The figure demonstrates the relationship between
circulating numbers of CD41CD45RA1 cell counts and PNCRM7
response in 127 recipients of an allogeneic HCT.
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\20% of patients who received PPV23 either as a pri-
mary or secondary vaccine (data not shown).
DISCUSSION
The development of more tolerable and effective
cytoreductive regimens and better supportive care
has increased not only the number of surviving trans-
plant patients returning to school and the workplace,
but the age of surviving population [21,23-30], individ-
uals particularly vulnerable to severe invasive pneumo-
coccal infections even in the absence of HCT [14].
Although the current CDC and EBMT vaccination
guidelines recommend the HIB conjugate vaccine fol-
lowing HCT [7,8], both recommend the use of PPV23
either as a single dose of PPV23 at 12 months (EBMT)
or sequential doses at 12 months and 24 months
(CDC). Nevertheless, several studies have shown a di-
chotomy between the responses of allogeneic trans-
plant recipients to pure polysaccharide vaccines
compared with protein-conjugated vaccines. Barra
et al. [31] demonstrated that only 4 of 20 (25%) adult
allogeneic transplant recipients given the pure polysac-
charide H flu vaccine developed a specific IgG
response compared with 11 of 20 (55%) patients given
the H flu conjugate vaccine (P\ .05). Guinan et al. [9]
studied the responses of 21 allogeneic and 14 autolo-
gous HCT recipients immunized with H flu conjugate
vaccine and the polysaccharide pneumococcal vaccine,
Pnu-immune (Lederle laboratory Division, American
Cyanamid Co., Pearl River, NY). Following the 24-
month immunization, only 19% of patients developed
protective titers against the 6 measured pneumococcal
serotypes (1, 3, 6A, 7F, 8, 9N), whereas 80% re-
sponded the HIB-conjugate vaccine. Our study simi-
larly demonstrates that the majority of patients who
fail the pneumococcal polysaccharide vaccine are capa-
ble of responding to HIB. In addition, we show that
77% of patients unable to respond to PNCRM7 re-
sponded to the conjugated HIB vaccine. The greater
response to the HIB conjugate versus the pneumococ-
cal conjugate vaccine may reflect the fact that the for-
mer vaccine contains a single protein-saccharide
conjugate, is inherently more immunogenic, and/or
expands memory T and B cell populations persisting
from prior childhood immunization or natural infec-
tion with Haemophilus influenzae.
To date, this is the largest study evaluating
PNCRM7 responses following allogeneic HCT and
the first to evaluate PNCRM7 responses in adult recip-
ients of an unmodified or T cell-depleted unrelated
HCT or adults following a T cell-depleted HCT
from any donor type. Although retrospective, it in-
cludes 80%of all patients transplanted during a defined
period (2002-2005) who survived disease-free.1 year.
Molrine et al [32] evaluated PNCRM7 response in 65unmodified HLA-matched related HCT recipients
(median age: 40 years) immunized with PNCRM7 at
3, 6, and 12 months, 30 of whom received grafts
from donors immunized before bone marrow harvest.
After the first immunization, antibody responses in the
immunized donor group were significantly higher for
5 of the 7 vaccine serotypes. Although response after
the third PNCRM7 immunization was not evaluable
in approximately 30% of the starting population
because of relapse (n 5 8), death from other causes
(n 5 5), thrombocytopenia (n 5 3), missed vaccines
(n5 2), or DLI (n5 1), 60% of the remaining patients
in both groups demonstrated significant pneumococcal
titers to all 7 serotypes. In a prospective, randomized
double-blind trial in adult recipients of an HLA-
matched related HCT, Kumar and colleagues [33]
compared the effect of vaccinating donor-recipient
pairs with a single PPV23 or PNCRM7. Donors
were vaccinated at least 2 weeks prior to stem cell
harvest; patients at 6 months post HCT. At 12
months post-HCT, the mean number of serotypes
for which a response was observed was 1.8 in the
PPV23 group and 3.1 in the PNCRM7 group. Sim-
ilar to the study of Storek et al. [34], no advantage to
pre-HCT immunization of the donor and/or host
with PPV23 was observed. Meisel et al. [35] studied
the response of 43 patients \17 years of age after
a related (45%) or unrelated (55%) HCT, demon-
strating that 74% of 43 patients responded to all 7
vaccine serotypes following the third immunization.
In a study of 30 children vaccinated according to
the Royal College of Paediatrics and Child Health
guidelines, Patel and colleagues [36,37] demon-
strated that 80% responded to each of the serotypes
contained in PNCRM7 when given 2 monthly doses
initiated at 15 months or 21 months following
an HLA-matched sibling (n 5 10) or unrelated
HCT (n 5 20), respectively. Considering the
poor response of transplant recipients to PPV23
[9-11,31,33,34] and its failure to reduce the inci-
dence of pneumococcal pneumonia even in healthy
middle-aged and elderly adults [38], this and the
above studies [33,35] support further trials of
PNCRM7 in adults and children following HCT.
The EBMT [4] and CDC guidelines [2] advocate
revaccination at fixed intervals following transplant, ir-
respective of patient age, donor or hematopoietic cell
type, intensity of conditioning, presence of cGVHD,
or use of posttransplant rituximab. Nevertheless,
many of these variables affect the kinetics of T and B
cell reconstitution following HCT [19,39], and likely
the ability of patients to respond and maintain protec-
tive titers following vaccination [40]. Only the Royal
College of Paediatrics and Child Health guidelines
stratify the timing of vaccination on the basis of donor
type (autologous and HLA matched sibling HCT ver-
sus all other donors) because of the delayed recovery of
1028 M. Pao et al.immune competence often associated with receipt of
an unrelated or HLA mis-matched donor transplant
[19,39]. Our study demonstrates that in older patients
response to PNCRM7 is significantly better in those
vaccinated after acquisition of minimal milestones of
immune reconstitution, milestones are reached at dif-
ferent time points post-HCT, and depend on age and
presence of cGVHD [19,39]. It also shows that even
within a population of patients who have achieved
minimal milestones of immune reconstitution, not all
patients respond, suggesting that qualitative and/or
quantitative differences in effector and memory helper
T and B cells are likely to differentiate responders and
nonresponders. It is possible that certain vaccines such
as tetanus and polio may elicit responses in the major-
ity of patients early post-HCT because of expansion of
memory T and B cells transferred with the graft. In
contrast, vaccines such as recombinant Hepatitis B
[41] and pneumococcus may constitute neoantigens
requiring generation of T and B cells from donor lym-
phoid progenitors developing within the host thymus
and other tissues of the lymphoid system. Our study
demonstrated a relationship between higher numbers
of circulating CD41CD45RA1 T cell numbers and
improved PNCRM7 response, suggesting that re-
sponders had achieved a significant level of reconstitu-
tion from precursor populations developing within the
host. The correlation, however, was not absolute.
Thus, impaired reconstitution of B cell precursors or
antigen-presenting cells may persist in some patients
despite de novo T cell reconstitution.
Although invasive pneumococcal infections occur
more frequently in patients with cGVHD, deaths
from these infections occur in patients with and with-
out cGVHD [1-5], as well as in autologous transplant
recipients [5]. This study, as well as the majority of
studies evaluating PNCRM7 response to date, have
not included large numbers of patients with cGHVD,
either by design or early death from cGVHD in en-
rolled patients [32,33,35,36]. Clearly, there is a need
to design multicenter prospective trials that do include
patients with limited and potentially extensive
cGVHD to identify the most effective vaccination
strategy to elicit protection against pneumococcal dis-
ease in the highest proportion of patients at the earliest
time possible. Inclusion in such trials of correlative
studies analyzing in vitro immune reconstitution
should identify immune characteristics most predictive
of early and durable immune responses.
Prior to the introduction of the conjugated pneu-
mococcal vaccine, 3000 cases of meningitis, 50,000
cases of bacteremia, 500,000 cases of pneumonia, and
7 million cases of otitis media because of pneumococ-
cus occurred annually in this country, causing 40,000
deaths per year (reviewed in [7]). Following wide-
spread vaccination of infants with PNCRM7, rates of
invasive pneumococcal disease because of penicillinresistant strains decreased from 6.3 cases in 1999 to
2.7 cases/100,000 in 2004 [42]. The reduction in pneu-
mococcal infections in children vaccinated with
PNCRM7 [13] and the seroconversion rates noted in
this and other studies, suggest that the impact of
PNCRM7 should be prospectively studied in a large
multicenter trial. To improve responses in older pa-
tients, strategies such as a primary series of 4 doses of
PNCRM7, the use of B andT cell immunomodulatory
agents, such as interleukin-7 [43] and/or the addition
of an adjuvant as incorporated in the recombinant
Hepatitis B vaccine, Fendrix, should be explored
[44]. To provide even more comprehensive coverage
in this at-risk population, future studies assessing the
PCV13 vaccine, currently being tested in healthy
adults and children [45] should be undertaken.
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